<DOC>
	<DOCNO>NCT01240473</DOCNO>
	<brief_summary>Kala azar ( KA ) visceral leishmaniasis ( VL ) endemic several district Bangladesh high incidence Mymensingh , Pabna Tangail district . ICDDR , B involve project improve surveillance KA Trishal , Mymensingh since 2005 . Improvement case detection necessary surveillance purpose well control . The aim pilot study ass new technique diagnosis KA use blood urine sample suspect case ; evaluate response treatment sodium stibogluconate resistance report India , consider part zone harbor disease agent Leishmania donovani transmit vector Phlebotomas argentipes ( sand-fly ) . No data currently available response sodium stibogluconate KA patient Bangladesh . Although number new drug evaluate treatment KA India Kenya , trial far conduct Bangladesh . A team researcher GlaxoSmithKline ( UK ) recently visit Bangladesh evaluate would possible conduct Phase-III clinical trial sitamaquine . They interact scientist ICDDR , B express interest help develop ICDDR , B 's capacity order include Bangladesh one sit plan , multi-centre , Phase-III trial sitamaquine ; India Nepal two possible site trial . The aim propose study train physician laboratory personnel preparation future drug trial ( ) KA well compare different test diagnosis might improve case detection field level use research purpose . The investigator also examine great detail different Leishmania specie circulate area Mymensingh whether treatment failure occurrence Post Kala azar Dermal Leishmaniasis ( PKDL ) associate certain specie .</brief_summary>
	<brief_title>A Pilot Study Capacity Building Multi-centre , Randomized Trial Treatment Kala Azar Bangladesh</brief_title>
	<detailed_description>Specific Aims : Primary objective : To develop capacity evaluate newer regimens treatment kala azar Bangladesh . Secondary objective : 1 . To evaluate novel diagnostic test kala azar include rK39 dipstick test serum ; KATEX urine ; PCR ( polymerase chain reaction ) blood clinical sample . 2 . To evaluate response treatment 28 injection SAG use PCR blood sample clinical sample . 3 . To transfer mini-exon PCR-RFLP technique ICDDR , B characterize prevalent Leishmania specie area Mymensingh response standard treatment SAG . 4 . We also analyze whether certain genotype associate occurrence PKDL whether mini-exon PCR suitable marker monitoring intra interspecies genetic evolution Leishmania specie . Research Design Methods : The patient propose study select three upazilla health complex Mymensingh per discussion government agency work area . If necessary , would go active surveillance enroll require number subject study . Patients In total , 200 consecutive case ( age &gt; 5 year ) meeting follow diagnostic criterion KA enrol study : ( ) fever &gt; 2 week ; ( ii ) least one follow criteria- splenomegaly , darken skin , weight loss ; ( iii ) positive rK39 dipstick test . Exclusion criterion include : ( 1 ) child five year age , ( 2 ) pregnant woman , ( 3 ) patient suffer simultaneously serious illness unrelated kala azar . Patients ( parents/guardians event minor ) meeting criterion , explain risk treatment SAG risk involve splenic aspiration procedure expert physician . Informed consent ( verbal write ) obtain patient ( parents/guardians event minor ) inclusion study . One hundred healthy individual live area enrol control evaluate PCR diagnostic test KA . Our field worker visit house community collect blood sample healthy volunteer inform consent . Study procedures assessment Splenic aspiration : Splenic aspiration perform 200 consecutive patient present clinical feature KA positive rK39 dipstick test . Splenic aspiration perform confirmation diagnosis study day 1 , day 29 ass cure disease . Thus , subject find positive rK39 dipstick test , standard pre-procedure test splenic aspiration e , g . hemoglobin estimation , bleed time , clot time , platelet count , perform . Splenic aspiration perform severely anemic ( Hb ≥ 6 mg/dl ) , platelet count &gt; 50,000/micro liter blood . Prothrombin time also check splenic aspiration PT 4 second prolong eligible study . All necessary treatment provide event hemorrhage follow procedure , include blood transfusion . If necessary , patient also transport Mymensingh Medical College Hospital , specialize treatment support . Treatment follow In Bangladesh , intramuscular administration sodium antimony gluconate ( SAG ; Albert David Ltd. , India ) , dose 20 mg/kg body weight , maximum dose 850 mg/day , twenty eight day current standard treatment patient KA . The pulse respiratory rate , blood pressure , temperature monitor 12 hourly interval treatment period . EKG perform clinically indicate . The treatment stop sign severe toxicity ( cardiotoxicity , renal failure , etc ) develop , patient treat standard dose amphotericin B . Hospitalization : All patient treatment offer stay Community-based Medical College Hospital entire period treatment SAG . The patient hospitalize treatment amphotericin B case treatment failure toxicity SAG . Follow : At end treatment , patient evaluate cure physical examination splenic aspiration . The subject follow six month show Scheme-2 . Diagnostic test evaluate rK39 dipstick test A finger-prick blood specimen collect capillary tube rK39 dipstick test . This method rapid time save . Parasitological diagnosis Splenic aspirate use parasitological diagnosis . A slide splenic aspirate prepare Giemsa stain . Two lab technician ICDDR , B train stain technique read slide . Randomly select slide send reference lab elsewhere Quality Control . Polymerase chain reaction ( PCR ) DNA Leishmania donovani collect blood sample detect use method describe Salotra et al . Sample collection DNA isolation : Collected blood specimen transport Parasitology Laboratory ICDDR , B , transfer 4°C process generally day . DNA extract 0.2 ml blood use QIAamp DNA blood mini kit ( Qiagen ) . PCR amplification : DNA culture parasite ( 1 ng ) clinical sample ( 100 ng ) take amplification use LdI primer describe . The reaction mixture ( 50 µl ) contain 10 mM Tris-HCl ( pH 8.3 ) 50 mM KCl , 1.5 mM MgCl2 , 200 µM concentration deoxynucleoside triphosphate , 50 ng primer , 1.25 U Taq DNA polymerase ( Gibco BRL ) . Each reaction mixture overlaid mineral oil , amplification perform thermal cycler ( Perkin-Elmer , Warrington , Great Britain ) program 40 cycle denaturation 94°C 1 min , anneal 45°C 1 min , extension 72°C 2 min , precede initial denaturation 2 min 94°C . Final extension 3 min 72°C . Products analyze electrophoresis 1 % agarose gel contain ethidium bromide ( 0.5 µg/ml ) TAE buffer ( 0.04 M Tris acetate , 0.001 M EDTA ) photograph UV illumination . Mini-exon PCR-RFLP : The mini-exon PCR-RFLP develop Swiss Tropical Institute ( STI ) ( Marfurth et al . 2003 ) . Sample Size Calculation Outcome Variable ( ) : The sample size 200 case 100 control base practical consideration meet primary objective capacity development study formally power hypothesis test . The emphasis investigate sensitivity specificity new diagnostic test present descriptive statistic confidence interval . Data Analysis : The sensitivity ( proportion correctly identify true positive result ) specificity ( proportion correctly identify true negative result ) calculate diagnostic test , 95 % confidence interval proportion calculate use Wilsons method . The positive negative predictive value also calculate use method describe Altman et al . The positive predictive value proportion patient positive result experimental diagnostic test correctly diagnose parasitological examination . Similarly negative predictive value proportion patient negative diagnostic test result correctly diagnose parasitological examination . The 95 % CI positive negative predictive value determine . These parameter would allow comparison diagnostic test 'gold standard ' parasitological examination .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Visceral</mesh_term>
	<criteria>KA enrol study : fever &gt; 2 week least one follow criterion splenomegaly , darken skin , weight loss positive rK39 dipstick test . child five year age\ pregnant woman patient suffer simultaneously serious illness unrelated kala azar ( example , tuberculosis , cancer , etc ) .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>kala azar</keyword>
	<keyword>visceral leishmaniasis</keyword>
	<keyword>diagnosis</keyword>
	<keyword>drug resistance</keyword>
	<keyword>Therapeutics</keyword>
	<keyword>Capacity Building</keyword>
</DOC>